Abstract:Previous studies have demonstrated that regurgitant fraction can be measured by using the proximal isovelocity surface area (PISA) method. For this study, we utilized this Doppler echocardiographic method to estimate the magnitude of mitral regurgitation in dogs with myxomatous mitral valve disease. Seventeen older, small dogs with chronic mitral regurgitation and no to mild myocardial failure were studied. A blinded observer judged the clinical severity of mitral regurgitation to be mild, moderate, or severe … Show more
“…In addition, one study demonstrated that the LA/Ao ratio was correlated significantly with the regurgitation fraction obtained by PISA (Gouni et al, 2007). In our study, the RF PISA showed higher values for group III (68.380% ± 16.153%) and the literature reports that values greater than 50% should be considered significant in cases of moderate to severe MR (Gouni et al, 2007), with values greater than 75% considered severe in small dogs (Kittleson and Brown, 2003 (Choi et al, 2004).…”
Section: Discussionsupporting
confidence: 62%
“…This fact is reported in the literature as a result of MR worsening, leading to the onset of signs of CHF (Carlsson et al, 2009). Moreover, the severity of MR is a major determinant of LA size in small animals (Kittleson and Brown, 2003). The LA/Ao ratio was greater in group III compared with the other groups; this could be justified by the fact that this ratio is directly influenced by the increase in the left atrium.…”
Section: Discussionmentioning
confidence: 60%
“…The mitral regurgitation area (MRA), vena contracta (VC) diameter and regurgitant fraction of proximal isovelocity surface area (RF PISA) were obtained from color flow mapping (Doppler) from the left apical four-chamber view, as described by previous studies (Kittleson and Brown, 2003;Muzzi et al, 2003;Gouni et al, 2007). For obtaining RF PISA, the color flow Doppler jet of mitral valve regurgitation was first identified with optimal gain setting.…”
“…In addition, one study demonstrated that the LA/Ao ratio was correlated significantly with the regurgitation fraction obtained by PISA (Gouni et al, 2007). In our study, the RF PISA showed higher values for group III (68.380% ± 16.153%) and the literature reports that values greater than 50% should be considered significant in cases of moderate to severe MR (Gouni et al, 2007), with values greater than 75% considered severe in small dogs (Kittleson and Brown, 2003 (Choi et al, 2004).…”
Section: Discussionsupporting
confidence: 62%
“…This fact is reported in the literature as a result of MR worsening, leading to the onset of signs of CHF (Carlsson et al, 2009). Moreover, the severity of MR is a major determinant of LA size in small animals (Kittleson and Brown, 2003). The LA/Ao ratio was greater in group III compared with the other groups; this could be justified by the fact that this ratio is directly influenced by the increase in the left atrium.…”
Section: Discussionmentioning
confidence: 60%
“…The mitral regurgitation area (MRA), vena contracta (VC) diameter and regurgitant fraction of proximal isovelocity surface area (RF PISA) were obtained from color flow mapping (Doppler) from the left apical four-chamber view, as described by previous studies (Kittleson and Brown, 2003;Muzzi et al, 2003;Gouni et al, 2007). For obtaining RF PISA, the color flow Doppler jet of mitral valve regurgitation was first identified with optimal gain setting.…”
“…Last, aortic stroke volume was assessed by pulsed wave Doppler trace of the aortic flow velocity by multiplying the aortic area by the velocity time integral using the left apical 5-chamber view. 23 …”
Section: Conventional Echocardiography and Doppler Examinationmentioning
Background: Pimobendan (PIMO) is an inodilator that may have some beneficial effects in canine degenerative mitral valve disease (MVD). However, little information is available about its cardiac effects in dogs without systolic myocardial dysfunction.Hypothesis: Compared to benazepril (BNZ), an angiotensin-converting enzyme inhibitor, PIMO may worsen valve regurgitation in early canine MVD.Animals: Twelve Beagles with asymptomatic MVD were randomized into 2 groups (n 5 6) receiving BNZ or PIMO at dosages of 0.25 mg/kg PO q24h and q12h respectively, for 512 days.Methods: The study followed a blinded, randomized, prospective, and parallel group design. After day 512, the dogs were necropsied, and cardiac histopathology was performed in a blinded manner.Results: A significant treatment effect was observed as soon as day 15 with increased systolic function in the PIMO group by comparison to baseline value as assessed by fractional shortening (P , .0001) and tissue Doppler variables (P 5 .001). Concurrently, the maximum area and peak velocity of the regurgitant jet signal increased (P , .001), whereas these variables remained stable in the BNZ group. Histologic grades of mitral valve lesions were more severe in the PIMO group than in the BNZ group. Moreover, acute focal hemorrhages, endothelial papillary hyperplasia, and infiltration of chordae tendinae with glycosaminoglycans were observed in the mitral valves of dogs from the PIMO group but not in those of the BNZ group.Conclusions and Clinical Importance: PIMO has adverse cardiac functional and morphologic effects in dogs with asymptomatic MVD. Additional investigation in dogs with symptomatic MVD is now warranted.
“…The regurgitant stroke volume (RSV) and the effective regurgitant orifice (ERO) were estimated by the proximal isovelocity surface area (PISA) method, which estimates regurgitation volume quantitatively [4,5,11].…”
ABSTRACT. Pimobendan has a dual mechanism of action: it increases myocardial contractility by increasing calcium sensitization to troponin C and it promotes vasodilation by inhibiting PDEIII. This study examined the effects of pimobendan on cardiac function, hemodynamics, and neurohormonal factors in dogs with mild mitral regurgitation (MR). The dogs were given 0.25 mg/kg of pimobendan orally every 12 hr for 4 weeks. With pimobendan, the heart rate and stroke volume did not change, but the systolic blood pressure gradually decreased and the degree of mitral valve regurgitation tended to decrease. Renal blood flow was significantly increased and the glomerular filtration rate was slightly increased at 2 and 4 weeks. Furthermore, over the 4-week period, the plasma norepinephrine concentration decreased significantly, the systolic index increased slightly, the left atrial diameter and the left ventricular diameters decreased significantly, and the heart size improved. Given these results, pimobendan appears to be useful for treating MR in dogs. However, further long-term studies of pimobendan involving a larger number of dogs with mild and moderate MR are needed to establish the safety of pimobendan and document improvements in quality of life. KEY WORDS: canine, mitral regurgitation, pimobendan.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.